Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.
We screened a panel of R5X4 and X4 human immunodeficiency virus type 1 (HIV-1) strains for their sensitivities to AMD3100, a small-molecule CXCR4 antagonist that blocks HIV-1 infection via this coreceptor. While no longer under clinical development, AMD3100 is a useful tool with which to probe interactions between the viral envelope (Env) protein and CXCR4 and to identify pathways by which HIV-1 may become resistant to this class of antiviral agents. While infection by most virus strains was completely blocked by AMD3100, we identified several R5X4 and X4 isolates that exhibited plateau effects: as the AMD3100 concentration was increased, virus infection and membrane fusion diminished to variable degrees. Once saturating concentrations of AMD3100 were achieved, further inhibition was not observed, indicating a noncompetitive mode of viral resistance to the drug. The magnitude of the plateau varied depending on the virus isolate, as well as the cell type used, with considerable variation observed when primary human T cells from different human donors were used. Structure-function studies indicated that the V1/V2 region of the R5X4 HIV-1 isolate DH12 was necessary for AMD3100 resistance and could confer this property on two heterologous Env proteins. We conclude that some R5X4 and X4 HIV-1 isolates can utilize the AMD3100-bound conformation of CXCR4, with the efficiency being influenced by both viral and host factors. Baseline resistance to this CXCR4 antagonist could influence the clinical use of such compounds.
Harrison
Jessamina E
JE
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Lynch
Jonathan B
JB
Sierra
Luz-Jeannette
LJ
Blackburn
Leslie A
LA
Ray
Neelanjana
N
Collman
Ronald G
RG
Doms
Robert W
RW
D000818:Animals; D001596:Benzylamines; D002478:Cells, Cultured; D000080027:Cyclams; D024882:Drug Resistance, Viral; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000502:physiology; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects*; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D011784:Quail; D019713:Receptors, CCR5 / Q000737:chemistry; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors* / Q000737:chemistry
D001596:Benzylamines; D000080027:Cyclams; D015699:HIV Envelope Protein gp120; D023581:HIV Fusion Inhibitors; D006571:Heterocyclic Compounds; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; C514793:gp120 protein, Human immunodeficiency virus 1; C088327:plerixafor
J Leukoc Biol. 2006 Nov;80(5):965-72
16923919
Nat Rev Drug Discov. 2003 Jul;2(7):581-7
12815382
Nat Med. 1996 Jul;2(7):760-6
8673921
J Virol. 2007 Apr;81(7):3240-50
17251281
J Virol. 2004 Aug;78(16):8654-62
15280474
J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1253-62
15385732
J Virol. 2001 Jun;75(12):5457-64
11356952
Curr Top Microbiol Immunol. 2006;303:97-120
16570858
Nature. 1996 Nov 14;384(6605):184-7
8906796
AIDS. 2001 Sep 7;15(13):1627-34
11546936
Science. 2002 Jun 28;296(5577):2354-60
12089434
Virology. 2004 Oct 10;328(1):74-88
15380360
Antimicrob Agents Chemother. 1997 Dec;41(12):2616-20
9420029
J Virol. 2005 Feb;79(3):1480-6
15650174
Methods Enzymol. 1997;288:118-33
9356991
AIDS. 2001 Sep 7;15(13):1671-7
11546942
Biochem Pharmacol. 2006 Aug 28;72(5):588-96
16815309
AIDS Res Hum Retroviruses. 2004 Jan;20(1):111-26
15000703
Virology. 2001 Mar 15;281(2):239-47
11277696
J Virol. 1998 May;72(5):4478-84
9557745
J Virol. 2004 Jul;78(14):7582-9
15220433
Nat Med. 1998 Jan;4(1):72-7
9427609
Cell. 1999 Mar 5;96(5):667-76
10089882
J Exp Med. 1997 Oct 20;186(8):1383-8
9334378
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54
12444251
J Virol. 2004 Mar;78(6):2790-807
14990699
J Virol. 2007 Sep;81(18):9956-66
17609282
PLoS Pathog. 2006 Feb;2(2):e10
16485036
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5215-20
10220446
J Virol. 2003 Jan;77(2):1610-3
12502877
Cell. 1996 Nov 15;87(4):745-56
8929542
J Virol. 1995 Jul;69(7):4453-62
7769705
Antiviral Res. 1997 Aug;35(3):147-56
9298754
J Virol. 2008 Jan;82(2):664-73
17977968
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11360-5
9736741
J Virol. 2005 Apr;79(7):4347-56
15767435
J Virol. 2005 Nov;79(21):13250-61
16227248
Virology. 2007 Aug 1;364(2):281-90
17428518
J Antimicrob Chemother. 2006 Apr;57(4):619-27
16464888
J Virol. 1996 Feb;70(2):689-96
8551604
J Virol. 1999 Sep;73(9):7117-25
10438797
Virology. 2007 May 25;362(1):163-78
17239419
Antimicrob Agents Chemother. 1994 Apr;38(4):668-74
7913308
PLoS Pathog. 2007 Aug 24;3(8):e117
17722977
J Virol. 2000 Jan;74(2):693-701
10623731
J Cell Biol. 2000 Oct 16;151(2):413-23
11038187
J Virol. 2003 Dec;77(24):13042-52
14645561
J Neurovirol. 2004;10 Suppl 1:91-6
14982745
J Exp Med. 1997 May 5;185(9):1681-91
9151905
J Clin Invest. 1999 Sep;104(5):R7-R11
10487781
Science. 2007 Sep 28;317(5846):1930-4
17901336
Virology. 2005 Jul 20;338(1):182-99
15935415
J Virol. 1997 Apr;71(4):3219-27
9060685
AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1715-24
11788023
J Virol. 2007 Mar;81(5):2359-71
17182681
J Virol. 1998 Mar;72(3):2509-15
9499115
AIDS Res Hum Retroviruses. 2005 Feb;21(2):171-89
15725757
Virology. 2007 Apr 25;361(1):212-28
17166540
J Virol. 1992 May;66(5):2934-42
1560532
J Virol. 1996 Oct;70(10):7318-21
8794390
Lancet. 2007 Jul 7;370(9581):81-8
17617275